Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.

Key Inclusion Criteria:

• Patients with newly diagnosed (within 6 months) Philadelphia chromosome positive CMLin chronic phase
• Patients must be previously untreated for CML with the exception of 6 months treatmentwith hydroxyurea and a maximum of 6 weeks treatment with imatinib
• Adequate end organ function
• Normal serum levels ≥ lower limit of normal (LLN) of potassium, magnesium, totalcalcium corrected for serum albumin or phosphorus, or correctable to within normallimits with supplements, prior to the first dose of study medication.

Key Exclusion Criteria:

• Known impaired cardiac function like long QT syndrome, history of myocardialinfarction or unstable angina in the past 12 months.
• Patients who are pregnant or breast feeding. Other inclusion/exclusion criteria might apply